STALEY CAPITAL ADVISERS’s Yarrow Bioscience YARW Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.5K	Hold	1,029	–	–	﹤0.01%	191
2026 Q1	$30.8K	Hold	1,029	–	–	﹤0.01%	182
2025 Q4	$29.9K	Hold	1,029	–	–	﹤0.01%	192
2025 Q3	$17.2K	Hold	1,029	–	–	﹤0.01%	197
2025 Q2	$84.9K	Hold	1,029	–	–	﹤0.01%	189
2025 Q1	$81.3K	Buy	1,029 +300	+41%	+$36.9K	﹤0.01%	185
2024 Q4	$122K	Hold	729	–	–	0.01%	173
2024 Q3	$68.6K	Hold	729	–	–	﹤0.01%	180
2024 Q2	$71.8K	Hold	729	–	–	﹤0.01%	177
2024 Q1	$112K	Hold	729	–	–	0.01%	177
2023 Q4	$85K	Buy	729 +260	+55%	+$40.5K	﹤0.01%	176
2023 Q3	$94.8K	Hold	469	–	–	0.01%	171
2023 Q2	$96.2K	Hold	469	–	–	0.01%	180
2023 Q1	$72K	Buy	469 +400	+580%	+$71.8K	﹤0.01%	174
2022 Q4	$9K	Hold	69	–	–	﹤0.01%	166
2022 Q3	$14K	Hold	69	–	–	﹤0.01%	167
2022 Q2	$24K	Hold	69	–	–	﹤0.01%	167
2022 Q1	$41K	Hold	69	–	–	﹤0.01%	178
2021 Q4	$64K	Buy	69 +13	+23%	+$14K	﹤0.01%	187
2021 Q3	$70K	Buy	56 +14	+33%	+$27.2K	﹤0.01%	180
2021 Q2	$132K	Buy	42 +14	+50%	+$55.4K	0.01%	177
2021 Q1	$171K	Buy	28 +14	+100%	+$102K	0.01%	178
2020 Q4	$79K	Buy	+14	New	+$88K	﹤0.01%	178

Other funds holding YARW

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

T3 Companies New York $93.7M AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $136M AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

STALEY CAPITAL ADVISERS's YARW Position: Q2 2026 in Review

STALEY CAPITAL ADVISERS held its Yarrow Bioscience (YARW) position steady in Q2 2026 at 1,029 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #191.

STALEY CAPITAL ADVISERS first reported a position in YARW in Q4 2020 and has held it in 23 quarters since. The position peaked at $171K in Q1 2021. 40 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

STALEY CAPITAL ADVISERS held 1,029 shares of Yarrow Bioscience worth $33.5K as of Q2 2026.
STALEY CAPITAL ADVISERS left its Yarrow Bioscience share count unchanged in Q2 2026.
Yarrow Bioscience made up ﹤0.01% of STALEY CAPITAL ADVISERS's portfolio in Q2 2026, its #191 holding.
STALEY CAPITAL ADVISERS first reported a position in Yarrow Bioscience in Q4 2020 and has held it in 23 quarters since.
STALEY CAPITAL ADVISERS's Yarrow Bioscience position peaked at $171K in Q1 2021.
40 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q2 2026, filed 11 Aug 2026.